Literature DB >> 15363474

The CLDN5 locus may be involved in the vulnerability to schizophrenia.

Z-Y Sun1, J Wei, L Xie, Y Shen, S-Z Liu, G-Z Ju, J-P Shi, Y-Q Yu, X Zhang, Q Xu, G P Hemmings.   

Abstract

The present study was designed to detect three single nucleotide polymorphisms (SNPs) located on 22q11 that was thought as being of particularly importance for genetic research into schizophrenia. We recruited a total of 176 Chinese family trios of Han descent, consisting of mothers, fathers and affected offspring with schizophrenia for the genetic analysis. The transmission disequilibrium test (TDT) showed that of three SNPs, rs10314 in the 3'-untranslated region of the CLDN5 locus was associated with schizophrenia (chi(2) = 4.75, P = 0.029). The other two SNPs, rs1548359 present in the CDC45L locus centromeric of rs10314 and rs739371 in the 5'-flanking region of the CLDN5 locus, did not show such an association. The global chi-square (chi(2)) test showed that the 3-SNP haplotype system was not associated with schizophrenia although the 1-df test for individual haplotypes showed that the rs1548359(C)-rs10314(G)-rs739371(C) haplotype was excessively non-transmitted (chi(2) = 5.32, P = 0.02). Because the claudin proteins are a major component for barrier-forming tight junctions that could play a crucial role in response to changing natural, physiological and pathological conditions, the CLDN5 association with schizophrenia may be an important clue leading to look into a meeting point of genetic and environmental factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363474     DOI: 10.1016/j.eurpsy.2004.06.007

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  28 in total

1.  Transmission disequilibrium test provides evidence of association between promoter polymorphisms in 22q11 gene DGCR14 and schizophrenia.

Authors:  H Wang; S Duan; J Du; X Li; Y Xu; Z Zhang; Y Wang; G Huang; G Feng; L He
Journal:  J Neural Transm (Vienna)       Date:  2006-01-25       Impact factor: 3.575

Review 2.  Blood-brain barrier: structural components and function under physiologic and pathologic conditions.

Authors:  Yuri Persidsky; Servio H Ramirez; James Haorah; Georgette D Kanmogne
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-06       Impact factor: 4.147

Review 3.  Drosophila, a genetic model system to study cocaine-related behaviors: a review with focus on LIM-only proteins.

Authors:  Ulrike Heberlein; Linus T-Y Tsai; David Kapfhamer; Amy W Lasek
Journal:  Neuropharmacology       Date:  2008-07-24       Impact factor: 5.250

Review 4.  The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders.

Authors:  Emily G Severance; Dag Tveiten; Lief H Lindström; Robert H Yolken; Karl L Reichelt
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 5.  Physiologic and anatomic characterization of the brain surface glia barrier of Drosophila.

Authors:  Michael K DeSalvo; Nasima Mayer; Fahima Mayer; Roland J Bainton
Journal:  Glia       Date:  2011-02-23       Impact factor: 7.452

Review 6.  Claudins and the modulation of tight junction permeability.

Authors:  Dorothee Günzel; Alan S L Yu
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

Review 7.  Environmental Exposures and Neuropsychiatric Disorders: What Role Does the Gut-Immune-Brain Axis Play?

Authors:  Shannon Delaney; Mady Hornig
Journal:  Curr Environ Health Rep       Date:  2018-03

Review 8.  The blood brain barrier: Insights from development and ageing.

Authors:  Conor Delaney; Matthew Campbell
Journal:  Tissue Barriers       Date:  2017-09-28

Review 9.  Analyses of the associations between the genes of 22q11 deletion syndrome and schizophrenia.

Authors:  Tadao Arinami
Journal:  J Hum Genet       Date:  2006-09-13       Impact factor: 3.172

10.  Association study between polymorphisms of the PARD3 gene and schizophrenia.

Authors:  Su Kang Kim; Jong Yoon Lee; Hae Jeong Park; Jong Woo Kim; Joo-Ho Chung
Journal:  Exp Ther Med       Date:  2012-02-23       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.